The Cigna Group (CI) Stock: Buy, Sell, or Hold?
CI - The Cigna Group
$280.76
-0.15 (-0.05%)
âŧ
5d:
-1.92%
30d:
+1.21%
90d:
-4.78%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 3, 2026 at $282.52 · last confirmed Sep 10, 2026
Strength: 5.3/10
Get Alerted When CI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CI is fairly priced but lacks strong directional signals. At -0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CI is fairly priced but lacks strong directional signals. At -0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$401.67
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$249.40
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CI is currently trading at $280.76, which is considered slightly high relative to its 30-day fair value range of $275.24 to $282.10. The stock's valuation (Forward PE: 8.4) is in line with its historical norms (8.6). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This pessimistic expectation contrasts with the company's recent 10.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CI is in a downtrend. The price is currently testing key support at $272.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CI scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $339.36 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CI is in a downtrend. The price is currently testing key support at $272.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CI scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $339.36 (+20.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$275.24 -
$282.10
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
76.2%
Protect Your Profits
Holding CI? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.9% below Wall St target ($339.36)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$275.24 -
$282.10
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$272.34
Resistance Level
$286.81
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.38
Wall Street Target
$339.36
(+20.9%)
Revenue Growth (YoY)
6.7%
Earnings Growth (YoY)
10.2%
Profit Margin
2.3%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
8.4 vs 8.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$278.79
(-1%)
2-Year Target
$276.84
(-1%)
3-Year Target
$274.91
(-2%)
3-Yr Target (if PE normalizes)
(PE: 8â9)
$281.98
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 9.8%)
$893.14
(+218%)
Base:
(SPY PE: 8.4, Growth: 9.8%)
$371.25
(+32%)
Bear:
(PE: 7.1, Growth: 9.8%)
$315.57
(+12%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 11.51 | Current EPS (TTM): $24.41
Bull Case
$423.91
(+51%)
Analyst growth 37.2%, PE expands to 12.7
Base Case
$385.37
(+37%)
Market implied 37.2%, PE stable at 11.5
Bear Case
$191.02
(-32%)
Severe decline -20.0%, PE contracts to 9.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.4 to 8.6
Stabilization Target:
$287.99
(+2.6%)
PE Expansion Potential:
+2.6%
Share & Embed Analysis
Last updated: September 12, 2026 11:29 AM ET
Data refreshes hourly during market hours. Next update: 12:29 PM
Data refreshes hourly during market hours. Next update: 12:29 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
28 analysts |
$116 | 50 HOLD |
|
UNH
UnitedHealth Group IncorâĻ |
STRONG BUY
27 analysts |
$475 | 49 HOLD |
|
ELV
Elevance Health Inc |
STRONG BUY
22 analysts |
$449 | 45 HOLD |
|
HUM
Humana Inc |
HOLD
26 analysts |
$419 | 49 HOLD |
|
CNC
Centene Corp |
BUY
19 analysts |
$72 | 47 HOLD |
Advanced CI Option Strategies
Professional options setups generated by AI based on today's CI price and gamma walls.
